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INTRODUCTION
Gastric cancer (GC) is the fourth most common cancer and 
the second leading cause of cancer-related deaths worldwide.1 
Although the survival rates of GC still remain poor,2 the overall 
5-year relative survival rate has increased, especially in North-
east Asia.3 Such high survival rates may be due to the effective-
ness of mass screening programs for early detection of GC us-
ing endoscopic examination and GC-specific biomarkers in this 
area.4 Therefore, early diagnosis of localized GC using screen-
ing programs is clinically important. Endoscopic examination 
is an ideal, highly reliable technique for early detection of GC, 
but its usefulness for GC screening is somewhat limited com-
pared to serological biomarkers due to its high cost and the risks 
associated with the invasive procedure. Serological tumor bio-
markers should have significant advantages as they are easily 
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accessible molecular markers with cost benefits. However, 
some limitations exist for clinical application of blood bio-
markers since very few blood biomarkers are available, such as 
carcinoembryonic antigen (CEA), cancer antigen (CA) 19-9, 
and CA 72-4, and the sensitivity of these serological biomark-
ers is low (20–30%) for diagnosis of GC.5-7 Therefore, research 
is still underway to identify effective serological biomarkers for 
GC. 
A recent report suggested that a disintegrin and metallopro-
teinases (ADAMs) participate in tumor cell proliferation, ad-
hesion and migration, and proteolysis, and there is growing 
evidence that specific ADAMs could play an important role as 
prognosis or predictive biomarker in human solid cancers.8-10 
These ADAMs regulate the activation of growth factors (e.g., 
EGF, TGF-a), cytokines (TNF-a), and integrins, which in turn 
promote tumor growth and metastasis.11 Moreover, targeting 
specific ADAMs by selective ADAM inhibitors is considered a 
promising therapeutic strategy.12 In a previous study, high ex-
pression of a disintegrin and metalloproteinase 8 (ADAM 8) 
in tumor tissue was significantly associated with advanced tu-
mor stages; especially, invasion of lymph nodes and distant 
metastasis were significantly associated with poorer overall 
survival in GC. Other previous study reported that serum lev-
els of ADAM 8 in GC patients were significantly higher than 
those in non-cancer group.13,14 Although emerging evidence 
suggests that ADAM 8 is a potential biomarker for predicting 
GC development or progression, very few studies have evalu-
ated correlations between blood ADAM 8 levels along GC car-
cinogenesis sequence and GC clinicopathological parameters, 
or their potential as a desirable blood biomarker for predicting 
GC development or progression. 
In this study, we evaluated the blood ADAM 8 levels along 
“gastritis–dysplasia–carcinoma” sequence of gastric carcino-
genesis,15 and analyzed the correlations between blood ADAM 
8 levels and GC clinicopathological features. Furthermore, we 
validated blood ADAM 8 as a potential biomarker candidate for 
GC and compared it to serum CEA, a pre-existing biomarker 
for gastrointestinal tumors, using human blood samples.
MATERIALS AND METHODS
Study groups
Study groups were classified into five groups according to “gas-
tritis-dysplasia-carcinoma” sequence of gastric carcinogenesis.15 
Normal control group included subjects with normal gastric 
mucosa or simple gastritis, high-risk group included patients 
with low-grade or high grade dysplasia, early GC (EGC) group 
included subjects with GC confined within submucosal layer 
without metastasis, AGC without metastasis group included 
subjects with GC beyond proper muscle layer without metas-
tasis, and AGC with metastasis group included subjects with 
GC beyond proper muscle layer with metastasis. 
For the initial training dataset, a total of 80 subjects were en-
rolled. The following numbers of subjects were enrolled in each 
group: 20 in normal control group, 10 in dysplasia group, 20 in 
EGC group, 20 in AGC without metastasis group, and 10 in AGC 
with metastasis group.
For independent validation dataset, a total of 241 subjects 
were enrolled. The following number of subjects were enrolled 
in each group: 70 in normal control group, 24 in dysplasia group, 
70 in EGC group, 50 in AGC without metastasis group, and 27 
in AGC with metastasis group.
All subjects underwent upper gastrointestinal endoscopy 
(Types XQ-260, Olympus, Tokyo, Japan) in gastroenterology 
out-patient clinics or health check-up center of Gangnam Sev-
erance Hospital, Yonsei University College of Medicine, due to 
gastric symptom or routine check-up. Diagnosis was made 
based on histological findings via biopsy or surgical specimens. 
All patients were diagnosed for the first time during the enroll-
ment period, and their blood samples were collected before 
they received any treatments. All patients in the cancer groups 
received imagining studies such as chest X-ray, abdominal-
pelvic helical computed tomography, and whole-body posi-
tron emission tomography (PET) scan for TNM stage. TNM 
stage of GC was evaluated according to the 7th International 
Union Against Cancer-TNM stage for GC via radiological stud-
ies or surgical findings.16 Histopathologic differentiation was 
diagnosed using Lauren classification. Subjects who suffered 
from chronic diseases such as liver cirrhosis, chronic renal 
disease, and diabetes mellitus were excluded. Subjects with 
other cancers and gastric neoplasm such as gastrointestinal 
stromal tumor, mucosa-associated lymphoid tissue lympho-
ma, and neuroendocrine tumors were also excluded. Addi-
tionally, patients with a history of any previous treatment for 
GC or its premalignant lesions were also excluded. 
Ethics statement
The current study was approved by the institutional review 
board of Yonsei University Health System (3-2019-0044), and 
all procedures were conducted according to the principles ex-
pressed in the Declaration of Helsinki. We enrolled subjects 
based on clinicopathological information such as age, gender, 
and disease contents using chart review blind to any personal 
information. Therefore, this study presented minimum risk to 
subjects and did not violate the right and welfare of subjects. 
We did our best to protect subjects’ privacy and anonymity.
Measurement of blood levels of ADAM 8, CEA, IL-23; 
SDF-1α/CXCL12; IL-8 and sCD40L
Blood ADAM 8 levels were measured using a commercially 
available ELISA kit (SEA620Hu, CLOUD-CLONE, Katy, TX, 
USA). Briefly, all reagents, blood samples, and standards were 
prepared. In addition,100 μL standards or blood samples were 
added to each well in the pre-coated 96-well plate and reacted 
at 37°C for 1 hour. After aspiration, the cells were washed three 
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times, and then 100 μL of the prepared Reagent B was added, 
followed by reaction at 37°C for 30 minutes. After five times of 
aspiration and washing, 90 μL of the substrate solution was 
added and reacted at 37°C for 10–20 minutes. Finally, blood 
ADAM 8 levels were measured at 450 nm using VERSA max 
microplate reader (Molecular Devices Co., Sunnyvale, CA, 
USA). Blood CEA levels were measured using Beckman Ac-
cess CEA assay (Beckman Coulter Inc., Chaska, CA, USA). 
Blood levels of interleukin-23 (IL-23), stromal cell-derived fac-
tor 1α (SDF-1α), interleukin-8 (IL-8), and soluble CD40 ligand 
(sCD40L) were measured by a commercially available MILLI-
PLEX MAP Human Cytokine/Chemokine Kit (Millipore, Bill-
erica, MA, USA) using a chemiluminescent immunoassay ac-
cording to the manufacturer’s instructions. Briefly, filter plate 
was pre-wetted with 200 microliters (μL) assay buffer for 10 
min at room temperature (RT), followed by vacuum removal 
of assay buffer. Twenty-five μL of standard or control was 
added to the appropriate well, and 25 μL assay buffer was 
added to the sample wells, but not the background well. Next, 
25 μL of the appropriate matrix solution was added to the back-
ground, standard, and control wells, followed by addition of 25 
μL sample to appropriate wells. After mixing, 25 μL beads were 
added, and the plate was incubated overnight at 4°C with 
shaking. After incubation, the fluid was removed and the plate 
was washed twice. Detection antibodies (25 μL) were added, 
and the plate was incubated for 1 h at RT with shaking. Strepta-
vidin-phycoerythrin (25 μL) was added to each well contain-
ing 25 μL detection antibodies and was incubated for 1 h at RT 
with shaking. Fluid was then removed, the plate was washed, 
and 150 μL sheath fluid was added. After re-suspension for 5 
min, the median fluorescent intensity was read on Luminex 
100TM IS (Luminex, Austin, TX, USA) and analyzed using logistic 
curve-fitting method to determine chemokine concentrations.
Statistical analysis
All assays were blinded and performed on the same day. Each 
value is expressed as mean with 25–75% standard deviation. 
Mean of each group was compared by ANOVA test with multi-
ple comparisons using post-hoc Bonferroni method. An inde-
pendent sample t-test was used to compare the means between 
cancer and non-cancer conditions. To evaluate the correlations 
between serum levels of tested values and clinicopathological 
parameters, Pearson’s correlation (coefficient, γp) and Spear-
man’s correlation (coefficient, γs) were performed, respective-
ly. Primary GC size was classified into three groups of <3 cm, 
3–5 cm, and >5 cm, in order to analyze the relationship be-
tween primary GC size and blood ADAM 8 levels. Receiver 
operating characteristic (ROC) curves were generated, and 
area under curve (AUC) was calculated to compare the diag-
nostic accuracy of each value to predict the presence of GC. 
Logistic regression analysis was performed to obtain the best 
sensitivity/specificity to predict the presence of GC as a sin-
gle-marker or as a multiple-markers panel. Each marker was 
included as a linear term.
RESULTS
Blood levels of ADAM 8 compared to CEA in five 
groups (initial training dataset)
A total of 80 subjects were enrolled in initial training dataset. 
Blood ADAM 8 and CEA were measured according to GC car-
cinogenesis (five disease groups), and then compared among 
groups. Table 1 shows that the mean of blood ADAM 8 was 
significant different among groups (ANOVA, p<0.001, Table 1, 
upper panel), and it increased along the carcinogenic se-
quences; mean of blood ADAM 8 were 1.7±2.6 ng/mL in nor-
mal/gastritis group, 15.3±13.3 ng/mL in dysplasia group, 53.9± 
36.9 ng/mL in EGC group, 82.8±52.6 ng/mL in AGC without 
distant metastasis, and 53.6±26.3 ng/mL in AGC with distant 
metastasis, respectively. Interestingly, blood mean levels of 
ADAM 8 were remarkably increased from the early stage of 
GC. Table 1 shows that blood mean levels of ADAM 8 were sig-
nificantly higher in EGC group compared to dysplasia group 
(high-risk, post-hoc Bonferroni, p<0.001) and normal control 
group (control, post-hoc Bonferroni, p<0.001). However, blood 
ADAM 8 levels were not significantly different among cancer 
groups, despite a tendency that these levels were maximized at 
locally advanced AGC without metastasis (post-hoc Bonferro-
ni between EGC and AGC, p=0.086) and then slightly decreased 
after distant metastasis without statistical significance. 
When the mean blood ADAM 8 levels were compared be-
tween cancer and non-cancer groups, levels in cancer groups 
(65.4±44.0 ng/mL) were significantly higher than those in non-
cancer groups (6.2±10.1 ng/mL, t-test, p<0.001, Table 1, lower 
panel). 
Blood mean of CEA levels were not significantly different 
among groups, except in metastatic cases of AGC groups (Ta-
ble 1, upper panel). This value was significantly elevated only 
in AGC with metastasis groups (ANOVA, p=0.013). When blood 
mean of CEA levels was compared between cancer and non-
cancer groups, no significant difference was found between 
cancer and non-cancer (p=0.235, t-test, Table 1, lower panel) 
groups. 
Blood levels of ADAM 8 compared to CEA according 
to GC carcinogenic sequences in the following 
independent validation dataset
To test the reproducibility of results from the initial training 
dataset, we used an independent validation dataset. A total of 
241 subjects were enrolled in validation dataset. Similar to the 
results of training dataset, mean of blood ADAM 8 were in-
creased along carcinogenic sequences; mean of blood ADAM 8 
were 6.4±8.7 ng/mL in normal/gastritis group, 23.7±16.0 ng/mL 
in dysplasia group, 54.5±42.7 ng/mL in EGC group, 67.9±55.1 
ng/mL in AGC without metastasis, and 55.0±29.7 ng/mL in 
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AGC with metastasis, respectively (ANOVA, p<0.001, Table 2, 
upper panel). This value was also remarkably increased from 
the early stage of GC, and it was not significantly different among 
cancer groups despite a tendency for it to be maximized at lo-
cally advanced AGC without metastasis (Table 2, upper panel).
When mean of blood ADAM 8 levels were compared be-
tween cancer and non-cancer groups, those of cancer groups 
(59.1±45.4 ng/mL) were significantly higher than those of non-
cancer groups (10.8±13.3 ng/mL, t-test, p<0.001, Table 2, low-
er panel), similar to the training dataset. 
Similar to the results of training dataset, blood mean of CEA 
levels was significantly elevated only in cases of AGC with meta-
static groups compared to other groups, with no significant dif-
ference found between cancer and non-cancer groups in vali-
dation dataset (Table 2, lower panel). 
Relationships between blood levels of ADAM 8 and 
clinicopathological characteristics of GC in validation 
dataset
Table 3 showed that blood ADAM 8 levels were not affected by 
age (Pearson’s correlation; γp=-0.064, p=0.319) and gender 
(Spearman’s correlation; γs=-0.095, p=0.143). Histopathologi-
cally, serum ADAM 8 levels were not significantly correlated 
with the histological differentiation of GC (γs=0.139, p=0.193), 
primary GC location (γs=0.058, p=0.397), and primary GC size 
(γs=0.121, p=0.249). This value was also not correlated with 
depth of invasion (T-stage, γs=0.197, p=0.085) and distant me-
tastasis (M-stage, γs=0.140, p=0.193) while it was closely corre-
lated with N-stage (γs=0.320, p=0.011). 
Diagnostic performance of blood ADAM 8, CEA, and 
their combination for prediction of GC presence in 
validation dataset
In validation dataset, ROC curve and calculated AUC of each 
value suggested that blood ADAM 8 has remarkable diagnos-
tic potential for prediction of GC presence, superior to blood 
CEA (Fig. 1); AUC was 0.90 (95% CI, 0.86–0.33) in blood ADAM 8 
and 0.56 (95% CI, 0.49–0.63) in blood CEA, respectively. Sen-
sitivity and specificity of blood ADAM 8 to predict the presence 
of GC were 73.7% and 86.2% (cut-off value, 30 ng/mL) as a sin-
gle-marker by logistic regression analysis (Table 4), which were 
Table 1. Serum Levels of ADAM 8 and CEA according to GC Carcinogenic Sequence (Upper Panel) and between Non-Cancer and Cancer Groups (Lower 
Panel) in Initial Training Dataset
Groups (N)
Normal/Gastritis 
(20)
Dysplasia 
(10)
EGC 
(20)
AGC 
(20)
Metastasis 
(10)
p value*
Non-cancer 
groups (30)
Cancer groups 
(50)
p value†
Serum ADAM 8 (ng/mL) 1.7±2.6 15.3±13.3 53.9±36.9 82.8±52.6 53.6±26.3 <0.001 6.2±10.1 65.4±44.0 <0.001
Serum CEA (ng/mL) 1.9±1.1 3.7±1.9 2.0±1.2 3.6±6.7   9.8±14.1   0.013 2.5±1.6 4.2±7.9   0.235
ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembryonic antigen; GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer.
Values are expressed as mean±standard deviation.
*One-way analysis of variance test with multiple comparisons using post-hoc Bonferroni method was used to compare differences in means among disease 
groups; †An independent sample t-test was used to compare differences in means between non-cancer and cancer groups. p<0.05 (two-tailed) was considered 
statistically significant.
Table 2. Serum Levels of ADAM 8 and CEA according to GC Carcinogenic Sequence (Upper Panel) and between Non-Cancer and Cancer Groups (Lower 
Panel) in Validation Dataset
Groups (N)
Normal/Gastritis 
(70)
Dysplasia 
(24)
EGC 
(70)
AGC 
(50)
Metastasis 
(27)
p value*
Non-cancer 
groups (94)
Cancer groups 
(148)
p value†
Serum ADAM 8 (ng/mL) 6.4±8.7 23.7±16.0 54.5±42.7 67.9±55.1 55.0±29.7 <0.001 10.8±13.3 59.1±45.4 <0.001
Serum CEA (ng/mL) 1.9±1.0 3.5±4.3 2.1±1.4 2.5±2.8 6.7±4.3 <0.001   2.3±2.4 3.0±3.1   0.053
ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembryonic antigen; GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer.
Values are expressed as mean±standard deviation.
*One-way analysis of variance test with multiple comparisons using post-hoc Bonferroni method was used to compare differences in means among disease 
groups; †An independent sample t-test was used to compare differences in means between non-cancer and cancer groups. p<0.05 (two-tailed) was considered 
statistically significant.
Table 3. Relationships between Serum ADAM 8 and Clinicopathological 
Characteristics of GC in Validation Dataset
  Clinicopathological characteristics Serum ADAM 8 [γs (p value)]
Age (yr)* -0.064 (0.319)
Gender (male:female) -0.095 (0.143)
Histology (well:mod:poorly:signet-ring)†   0.139 (0.193)
Tumor location (lower:middle:upper)   0.058 (0.397)
Tumor size (<3 cm; 3–5 cm and >5 cm)‡   0.121 (0.249)
T-stage (T1a:T1b:T2:T3:T4)§   0.197 (0.085)
N-stage (N0:N1:N2:N3)§   0.320 (0.011)
Distant metastasis (M0:M1)§   0.140 (0.193)
ADAM 8, a disintegrin and metalloproteinase domain 8; GC, gastric cancer.
‘γs’ means ‘Spearman’s correlation coefficient. p<0.05 (two-tailed) was consid-
ered statistically significant’.
*This was a continuous variable. Therefore, correlation was evaluated by 
Pearson’s correlation (γp); †‘Well:mod:poorly:signet-ring’ means ‘well-differ-
entiated carcinoma:moderate-differentiated carcinoma:poorly-differentiated 
carcinoma:signet-ring cell carcinoma’; ‡Tumor size was classified into three 
groups: <3 cm, 3–5 cm, and >5 cm; §TNM stage was evaluated according to 
the 7th International Union Against Cancer-TNM stage guidelines. 
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superior to those of blood CEA (23.1% and 91.4%; cut-off value, 
4 ng/mL), respectively. 
Since the elevated pattern of blood ADAM 8 and CEA were 
significantly different from each other according to GC stage, 
combination of these serum markers as a multiple-markers 
panel was expected to be synergistic. As a multiple-markers 
panel, combination of serum ADAM 8 (cut-off value, 25 ng/
mL) and CEA (cut-off value, 5 ng/mL) exhibited increased di-
agnostic accuracy compared to a single marker, remarkably 
(sensitivity, 81.8%; specificity, 84.0%; Table 4). 
Correlations between blood levels of ADAM 8 and 
cancer-associated cytokines in validation dataset
To investigate the role of blood ADAM 8 in carcinogenesis and 
progression of GC, the correlations between blood ADAM 8 
levels and several GC-associated pre-inflammatory or pro-
angiogenic cytokines levels were evaluated using validation 
dataset. Table 5 shows that blood ADAM 8 levels were closely 
correlated with blood IL-23 (γp=0.235, p=0.036) and blood SDF-
1α/CXC chemokine ligand 12 (CXCL12) (γp=-0.233, p=0.037), 
while blood ADAM 8 levels were not closely correlated with 
blood IL-8 (γp=0.113, p=0.313) and blood sCD40L (γp=0.043, 
p=0.702). That is, blood ADAM 8 was closely correlated pre-
inflammatory cytokines (IL-23, SDF-1α/CXCL12), while it was 
not correlated with pro-angiogenic cytokines (IL-8, sCD40L).
DISCUSSION
ADAM 8 is a transmembrane protein that belongs to the ADAM 
family of proteins that mediate cell adhesion and cell migration 
through the cleavage of membrane-bound cytokines, growth 
factors, and receptors.17 A previous report has suggested that 
ADAM 8 ectodomain is cleaved by ADAM 8 itself.18 ADAM 8 
was known to play potential roles in inflammatory and allergic 
processes,19 and further studies have shown that its overex-
pression is associated with progression and poor survival in 
various solid tumors.20-22 A previous study reported that ADAM 8 
in tumor tissue was an independent indicator of lymph node 
metastasis in human GC; however, its precise effects on GC 
progression and prognosis remain unclear. In this study, we in-
vestigated the clinical usefulness of blood ADAM 8 as a blood 
biomarker for early detection of GC. We evaluated the clinical 
implications of blood ADAM 8 as a biomarker for early diag-
nosis of GC as a single-marker or a part of combination panels, 
compared to blood CEA, a pre-existing gastrointestinal tumor 
marker, according to the guideline of Standards for Reporting of 
Diagnostic Accuracy statement.23 We found that blood levels of 
ADAM 8 were significantly different among groups (ANOVA, 
all p<0.001), and were increased significantly along the GC 
carcinogenesis in both initial training and following indepen-
dent validation datasets (Tables 1 and 2, upper panel). These 
levels were significantly different between cancer and non-
cancer groups (t-test, all of p<0.001; Tables 1 and 2, lower pan-
el). Interestingly, this value was elevated from the EGC, differ-
ent from many pre-existing serum biomarkers such as CEA. 
This means that the use of blood ADAM 8 may be very mean-
ingful in predicting the presence of GC in replacement of en-
doscopy as a screening tool. However, blood ADAM 8 levels 
were not significantly different among cancer groups, although 
Table 5. Pearson’s Correlations among Serum Levels of IL-23, SDF-1α, 
IL-8, sCD40L, and ADAM 8 in Validation Dataset
IL-23 SDF-1α IL-8 sCD40L
ADAM 8 0.235 (0.036)* -0.233 (0.037)* 0.113 (0.313) 0.043 (0.702)
ADAM 8, a disintegrin and metalloproteinase domain 8; IL-23, interleukin-23; 
SDF-1α, stromal cell-derived factor 1α; IL-8, interleukin-8; sCD40L, soluble CD40 
ligand.
Values are presented as γp (p value). ‘γp’ means ‘Pearson’s correlation coeffi-
cient’. p<0.05 (two-tailed) was considered statistically significant.
*Statistically significant values.
Table 4. Comparison of Sensitivity and Specificity of Serum ADAM 8, CEA 
and Their Combination as Single Markers and/or as a Multiple-Markers 
Panel for Prediction of GC Determined by Logistic Regression Analysis in 
Validation Dataset
Marker panel*
Cut-off values 
(ng/mL)
Sensitivity 
(%)
Specificity 
(%)
ADAM 8 30 73.7 86.2
CEA 5 23.1 91.4
ADAM 8+CEA 25, 5 81.8 84.0
ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembry-
onic antigen; GC, gastric cancer.
*Each marker was included as a linear term and evaluated as part of a panel of 
one to two markers in combination.
1.0
0.8
0.6
0.4
0.2
0.0
0.0                   0.2                  0.4                  0.6                0.8                 1.0
1-specificity
Se
ns
iti
vit
y   ADAM 8
  CEA
  Reference line
Markers ADAM 8 CEA
AUC 0.896 0.558
Fig. 1. ROC curves and AUCs of blood ADAM 8 and CEA for prediction of 
gastric cancer in independent validation dataset. ADAM 8, a disintegrin 
and metalloproteinase domain 8; CEA, carcinoembryonic antigen; AUC, 
area under curve; ROC, receiver operating characteristic curve. 
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there was a tendency that these levels were maximized at lo-
cally advanced AGC without metastasis (post-hoc Bonferroni 
between EGC and AGC, p=0.086), and then slightly deceased 
after distant metastasis. According to Spearman’s correlation 
analysis (Table 3), no association was found between serum 
ADAM 8 and either tumor size, depth of invasion (T-stage), 
and distant metastasis of GC. However, significantly close as-
sociation was found between serum ADAM 8 and lymph 
node involvement (N-stage) (Table 3). A previous study re-
ported that ADAM 8 protein expression in GC tissues was sig-
nificantly correlated with invasion depth (T-stage), lymph 
node involvement (N-stage), and vessel invasion.13 The cause 
of difference between our results and those of previous stud-
ies may have originated from the difference in sample types 
(tissue vs. blood) or relatively small sample size of our study, 
especially in distant metastatic cases. Therefore, a large-scale 
study should be performed in the future to confirm these re-
sults.
Blood ADAM 8 showed higher diagnostic sensitivity than 
blood CEA (Fig. 1 and Table 4). Blood ADAM 8 alone showed 
73.7% sensitivity and 86.2% specificity for diagnosis of GC. 
When blood ADAM 8 and blood CEA were combined, this 
panel showed higher sensitivity for diagnosis of GC (sensitivi-
ty; 81.8%, specificity; 84.0%). We also evaluated the diagnostic 
performance of ADAM 8 for GC using ROC curve and calcu-
lated AUC in validation dataset (Fig. 1), and found that AUC 
(0.90, 95% CI, 0.86–0.33) was remarkable for diagnostic perfor-
mance for GC. The sensitivity, specificity, and AUC of blood 
ADAM 8 in our study were comparable or superior to those of 
a previous study that evaluated panel of five blood biomark-
ers, including ADAM 8.14 Overall, the sensitivity and specificity 
were improved when ADAM 8 and serum CEA were combined 
(81.8% and 84.0% at cut-off point, 25 ng/mL, 5 ng/mL, respec-
tively). 
In order to know more detailed role of blood ADAM 8 in 
carcinogenesis and progression process of GC, we evaluated 
the correlations between blood levels of ADAM 8 and pre-in-
flammatory cytokines (IL-23, SDF-1), and between blood lev-
els of ADAM 8 and pro-angiogenic cytokines (IL-8, sCD40L) 
using validation dataset. In this study, blood ADAM 8 levels 
were closely correlated with blood IL-23 and serum SDF-1, 
while blood ADAM 8 levels were not closely correlated with 
blood IL-8 and serum sCD40L (Table 5). These results imply 
that blood ADAM 8 may be closely correlated in cancer-asso-
ciated inflammation for cancer initiation or local invasion from 
the early stage of GC. However, blood ADAM 8 may be not be 
correlated in angiogenesis for distant metastasis. 
One of the limitations of this study was that we did not eval-
uate the prognosis of GC patients according to serum levels of 
ADAM 8 directly through overall survival analysis, as observa-
tion period inthis study was too short to evaluate the overall 
survival of patients with GC. In a previous study, survival 
analysis demonstrated that patients with positive ADAM 8 ex-
pression in GC tissue had shorter survival times compared to 
those with negative expression. Further large-scale studies 
with long-term follow-up period should be performed in the 
future to confirm our current results.
In conclusion, we demonstrated that blood levels of ADAM 
8 were closely associated with the development and progres-
sion of GC. However, high-levels of these values could not re-
flect the high probability of the presence of distant metastasis 
of GC. Additionally, blood levels of ADAM 8 demonstrated re-
markable sensitivity and performance to predict the presence 
of GC, compared to blood CEA. To our knowledge, this is the 
first report to measure the serum levels of ADAM 8 along GC 
carcinogenic sequences, and the first to evaluate the clinical 
significance of high-levels of serum ADAM 8 in GC. Addition-
ally, this study is the first to report that combined blood ADAM 
8 and CEA are promising biomarkers for GC as part of multi-
ple-marker panels.
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